Related Experiment Video
Updated: Jun 15, 2026
09:44
Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis
Published on: June 13, 2021
2.8K
Targeting Azole-Resistant Candida albicans: Tetrapeptide Tuftsin-Modified Liposomal Vaccine Induces Superior Immune
Masood A Khan1, Arif Khan1, Abdullah M Alnuqaydan1
1Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah 51412, Saudi Arabia.
Vaccines
|June 27, 2025
Summary
A novel liposomal vaccine, Tuft-lip-WCAg, provides complete protection against drug-resistant Candida albicans in mice. This immunoprophylactic strategy shows promise for immunocompromised individuals facing invasive candidiasis.
Area of Science:
- Mycology
- Immunology
- Vaccinology
Background:
- Candida albicans is a significant fungal pathogen, especially in immunocompromised individuals.
- Rising fluconazole resistance in C. albicans necessitates new therapeutic approaches.
- Systemic candidiasis poses a severe health risk, requiring effective preventative measures.
Purpose of the Study:
- To assess the prophylactic efficacy of a novel liposomal vaccine, Tuft-lip-WCAg, against systemic candidiasis.
- To evaluate the immune response generated by the Tuft-lip-WCAg vaccine in a murine model.
- To determine the protective potential of Tuft-lip-WCAg against fluconazole-resistant C. albicans.
Main Methods:
- A murine model of systemic Candida albicans infection was utilized.
- Vaccine efficacy was determined by survival rates and fungal burden.
- Immunological assessments included antibody titers, T cell proliferation, and cytokine analysis (IFN-γ, IL-4).
Main Results:
- Tuft-lip-WCAg vaccination resulted in 100% survival and no detectable fungal burden by day 40.
- Vaccinated mice showed significantly increased antibody titers, IgG2a levels, and T cell proliferation.
- Splenocytes from immunized mice produced elevated levels of IFN-γ and IL-4, indicating a balanced Th1/Th2 response.
Conclusions:
- The Tuft-lip-WCAg formulation is a safe and immunogenic vaccine candidate.
- It offers complete protection against drug-resistant Candida albicans in a preclinical murine model.
- Tuft-lip-WCAg represents a promising immunoprophylactic strategy for high-risk populations.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:20Candidiasis
Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...